Two Randomized Controlled Trials News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Two Randomized Controlled Trials. Real-time updates on events, politics, business and more.

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice -January 18, 2024 at 12:01 pm EST

January 18, 2024

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application...

Mahboobeh Mahdavinia Jonathan Neely Rakeshk Chandra Jamesn Palmer John Messina Ramy Mahmoud

Source: marketscreener.com

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

September 30, 2021

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and...

United States Catalina Loveman Kevin Hern Christine Chiou Marlo Scott Eli Lilly

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Two Randomized Controlled Trials News Today

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice -January 18, 2024 at 12:01 pm EST

OLUMIANT&#xAE; Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

Explore More Categories

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata